Pfizer's breast cancer drug combo falls short of survival goal

Pfizer Inc (PFE.N) said on Monday a combination of its breast cancer drug, Ibrance, and another drug was not statistically significant in extending overall survival in certain patients, the secondary goal of a late-stage trial.